"Over the next 3-4 years, we will diversify our entire business from ARV focussed API and formulations to broadly diversified revenue. No therapy will contribute significantly from 2025," said Satyanarayana Chava, Founder and CEO of Laurus Labs in an interview to Moneycontrol.Laurus Labs to focus on non-HIV drugs to drive future growth
"Over the next 3-4 years, we will diversify our entire business from ARV focussed API and formulations to broadly diversified revenue. No therapy will contribute significantly from 2025," said Satyanarayana Chava, Founder and CEO of Laurus Labs in an interview to Moneycontrol.
Subscribe to:
Post Comments (Atom)
-
The company did not export units last month while it had dispatched 804 Etios units in in June 2019.
-
Google has tried for years to get Samsung, the world#39;s leading mobile device maker by units sold, to drop its own services and give grea...
-
The company, one of the leading manufacturers of soda ash, had initiated the process of carving out its textiles business into GHCL Textile...
No comments:
Post a Comment